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ABSTRACT 
Introductions: This study was done to evaluate clinical profile of Henoch-
Schönlein purpure (HSP) in children admitted in Patan Hospital. 
 
Methods:  The medical records of all children admitted in children ward 
with the diagnosis of HSP from January 2008 to December 2015 were 
analysed for clinical presentation, management and outcome. 
 
Results: Of 59 patients, 37(63%) were boys. The patients’ ages ranged 
from 15 months to 14 years with a mean of 8.3 years. Approximately two 
third cases presented during winter and autumn. Upper respiratory tract 
infection preceded HSP in 37 and anti streptolysin O titer was positive in 6 
of the 13 (46%) children tested at presentation. Skin purpura was seen in 
59 (100%), arthritis or arthralgia 48 (81%), gastrointestinal manifestation 
47 (80%) and renal involvement 16 (27%). Forty one (69%) patients 
received corticosteroid therapy. All children made a full recovery, two 
with nephritis continued to have hypertension, hematuria and 
proteinuria. Symptoms occurred in 6 (10%) over a period one month to 
two years follow up.  
 
Conclusion: The HSP in children had seasonal occurrence, skin rash, pain 
abdomen with mild disease and recovered well.  
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INTRODUCTIONS 
 
Henoch-Schönlein purpura (HSP) is the most 
common vasculitis of childhood. Approximately 
90% of HSP cases occur in children between the 
ages of 3 and 10 year.1 It is characterized by non-
thrombocytopenic purpura, arthritis or arthralgia, 
abdominal pain, gastrointestinal hemorrhage and 
renal manifestations.2 The classical triad seen is 
palpable purpura, abdominal colicky by pain or 
hemorrhage and joint pain. However, diagnostic 
confusion can arise in cases who present with the 
absence of cutaneous features.3 This study 
evaluates the clinical profile of HSP in children 





The medical records of all children admitted in 
children ward with the diagnosis of HSP from 
January 2008 to December 2015 were retrieved 
and analyzed. Diagnosis of HSP was based on 
presensse of at least two of the following four 
criteria: 1) Palpable purpura not related to 
thrombocytopenia, 2) Age 20 years or younger at 
onset, 3) Bowel angina, 4) Histology changes 
showing granulocytes in the walls of arterioles or 
venules.4 The demography (age and gender) and 
clinical characteristics, laboratory data at onset, 
therapy, and recurrence were studied. Renal 
biopsies were graded according to the 
classification of the International Study of Kidney  
Disease in children (ISKDC).5 
 
Recurrences was defined as a new flare-up of skin 
rash or other systemic complications following 
resolution of the disease for at least one month.6 
Continuous variables (such as age) were expressed 
as mean, median, and range. Absolute numbers as 
well as percentages were presented for the study 





There were total of 59 (m 37, f 22) children with 
HSP. All patients had nonthrombocytopenic 
palpable purpura, distributed mainly over the legs, 










Figure 1. Seasonal occurrence of Henoch-Schonlein purpura 
(HSP) in children (n=59) 
 
Table 1. Demography and etiology of HSP in children (n=59)  
 
 
Table 2.  Clinical features of 59 patients with HSP 
Symptom n (%) 
Skin 59 (100) 
Joint Involvement 48 (81.3) 
Arthritis/Arthalgia 48 (81.3) 
Ankle/Feet 45 (76.2) 
Knee 41 (69.4) 
Wrist/Hand 16 (27.1) 
Elbow 13 (22.0) 
Gastrointestinal Involvement 46 (80.0) 
Abdominal Pain 44 (74.5) 
Malena 20 (33.8) 
Vomiting 25 (42.3) 
Hematechezia 6 (10.0) 
Hematemesis 2(3.3) 
Intussusceptions  0 (0) 
Renal Involvement 16 (27.0) 
Microscopic Hematuria 12 (20.3) 
Macroscopic Hematuria 2 (3.3) 
Proteinuria 9 (15.2) 
Nephrotic Syndrome 5 (8.0) 
Edema of face, dorsum of feet, hand 3(5.0) 
Seizure 2 (3.3) 
Recurrence 6 (10.0) 
Demographic Data   
Age of onset (years)  




Male 37 (62.7) 
Female 22 (37.2) 
Male to Female Ratio  1.6 : 1 
Age Distribution (years)  
< 5 13 (22) 
> 5 to < 10 31 (52.5) 
> 10 15 (25.4) 
Season Pattern  
Winter 22 (37.2) 
Autumn 17 (28.8) 
Spring 12 (20.3) 
Summer 8 (13.5) 
Etiological Factor 33 (56.0) 
                 URTI 22 (37.2) 
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Prednisolone 1-2 mg/Kg/day was prescribed to 
41/59 (69%) patients for renal involvement, or 
joint and GI manifestations. All patients made a full 
recovery. Two and persistent proteinuria were on 
regular followup. 
 
The c-reactive protein, elevation of ESR and 
lecucocytosis were seen children with HSP, (Table 
3).  
 
Table 3.  Laboratory findings among HSP patients 
Laboratory Test Positive/Tested 
    n            (%) 
Leukocytosis (WBC > 
11000/mm3) 
28/59     (47.4) 
Thrombocytosis (platelets > 
500000 cell/mm3 
14/59     (23.7) 
Anemia (Hemoglobin < 11 
gm/dl) 
9/46       (19.5) 
Elevated ESR 20/39     (51.2) 
Positive ASO titer ( > 200 
IU/ml) 
6/13       (46) 
Increased C-reactive protein 12/21     (57.1) 
Positive throat culture 0/19       (0) 
Low C3 3/13       (23) 
Renal Biopsy 2/2         (100) 
WBC: While Blood cells. ESR – erythrocyte sedimentation rate. 





In the present study, nearly 75% of children were 
less than 10 years of age. Male to female ratio was 
1.68:1. Similar results were obtained by Cakir 
Murat et al6 who in their study of 116 children, 73 
(63%) were male and 43 (37%) females with a ratio 
of 1.69:1. Naveed Shahzad et al7 in their 27 
patients, 17 (63%) males and 10 (37%) females 
with a ratio of 1.7:1and A slight female 
preponderance was found in some studies.8.9  
 
Henoch-Schönlein purpura occurs throughout the 
year, but a number of studies have noted seasonal 
variation, with most patients presenting from fall 
through spring and a paucity of cases in the 
summer months.10,11 In the current study, there 
were more patient in winter and fall (66%). Mahar 
khadar et al12 found distribution of admission was 
highest in winter months. Nearly 56% of patients 
had a potential trigger event before HSP onset, 
which is consistent with study done by Amer A 
Lardhi in 2012 found potential trigger event before 
HSP onset in 55% of cases.13 
 
The main clinical features of HSP included purpuric 
rash, GI symptoms, joint and kidney manifestation. 
Classic skin purpura was present in all patients in 
current study. Similar results were observed by I. 
Kumar et al.14 Rashes were often seen in the lower 
extremities and buttocks, but some also had 
involvement of the arms and face. Joint 
involvement including arthritis and arthralgia is 
common occurring in up to 75% of children with 
HSP, with a predilection for the lower extremities.1 
It was observed in 81% of the patients in our study 
and mainly affecting ankles and knees. The joints 
of the upper extremities were involved in few 
patients.  
 
Gastrointestinal manifestations of HSP occur in up 
to 80% of children with HSP and include abdominal 
pain, vomiting, diarrhea and melena; 
Intussusception, mesenteric ischaemia and 
intestinal perforation are uncommon.1 
Gastrointestinal manifestation has been described 
in up to 75% in some series.15,16 Abdominal pain 
was present in 66.6% of cases reported by Naveed 
Shahzad et a. in May 2015.7 Whereas Saulsbury 
FT17 found that abdominal pain was present in 63% 
of patients. Abdominal colic, vomiting and gross or 
occult bleeding are the dominant features of GI 
involvement 46 (80%) patients in our study. None 
of the patients developed intussusception or 
perforation in the current study.  
 
The long term morbidity and mortality of HSP are 
related to the severity of renal involvement. The 
reported incidence of renal involvement varies 
from 10-50%; with end stage renal disease in 
5%.18,19 In the present study, renal involvement 
occurred in 16 (27.0%) patients. Amer A. Lardhi 
found renal involvement in 19 out of 78(24%) 
patients.13  
 
The low incidence of renal involvement in the 
current series may be related to local variations in 
causative and environmental factors. The main 
clinical features of renal involvement in the 
present study were microscopic hematuria with or 
without proteinurea, and nephritic syndrome. 
19  
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Nephritic syndrome developed in 5(31%) patients. 
The overall outcome of HSP nephritis is good. All 
patients with nephritis in the present study made a 
complete recovery, but two patients who had 
hypertension, hematuria and persistent 
proteinuria required treatment for hypertension 
and were on regular followup.  
 
Other less common potential manifestations of 
HSP are orchitis, carditis, inflammatory eye disease 
testicular torsion, and pulmonary hemorrhage.1 
which were not present in our study. Seizure are 
rare manifestations of CNS involvement in patients 
with HSP.10,20 Two patients (3.3%) developed 
seizure because of hypertensive encephalopathy in 
this study which is also consistent with study done 
by Amer A. Lardhi who found seizure in 2.5% of 
cases.13  
 
In agreement with literature,18,20,21 the present 
data show increased ESR in 20/39 (51%), CRP in 
12/21 (57%), leukocytosis in 28/59 (47%), Table 3. 
Complement component were decreased in 3/13 
(23%). Decreased complement levels are reported 
in 10-18% and increased serum IgA in 0-62% but 
are not routinely measured.18,22,23 
 
The frequency of relapses varies from 5-66%.23,24 In 
the present study, 6 (10%) patients relapsed within 
the first 2 years. These figures are similar to Amer 
A. Lardhi who found 8% relapse in his patients 
within the first 2 years.13 
 
Some of the patients with HSP require only 
supportive measures. Corticosteroid therapy 
reduces the duration and severity of abdominal 
and joint pain but corticosteroids do not prevent 
the development of nephritis, or alter the natural 
course of HSP.20,25 However, 41 (69%) patients in 
the present study received steroid for GI and renal 
involvement. Patients with severe HSP nephritis 
may require other regimen of treatment. This may 
include high dose steroid, azathioprine, 
cyclophosphamide, mycophenolate mofetil, 
intravenous immunoglobulin and plasma 
pheresis.26,27 
 
In this study, we did not include all cases attended 
the outpatients departments in pediatrics, and 
dermatology. Therefore, these cases might 





The HSP in children had seasonal occurrence, skin 
rash, pain abdomen with mild disease and 
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